In late September and early October 2026, Travere Therapeutics reported new FILSPARI® (sparsentan) data across IgA ...

(Nasdaq: TVTX) today announced that it will share nine new data presentations, including five oral presentations, at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, CO, October 21 ...

(Nasdaq: TVTX) today announced that on October 10, 2026, the Compensation Committee of its Board of Directors granted ...

The package includes 36,000 options at a $52.02 exercise price per share and 142,580 restricted stock units, vesting over ...

Travere Therapeutics has delivered a very large share price gain over the past few years, which naturally puts the focus on ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Travere Therapeutics has announced that Bradley L. Campbell will become President and Chief Executive Officer on December 1, 2026, succeeding Eric Dube, Ph.D., who has decided to step down after ...

Detailed price information for Travere Therapeutics Inc (TVTX-Q) from The Globe and Mail including charting and trades.

Travere to Present New Data Supporting FILSPARI® (sparsentan) as Foundational Treatment in IgA Nephropathy and FSGS at ASN Kidney Week 2026 Two-year SPARTAN data show 75% complete proteinuria ...